Trevi Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Trevi Therapeutics, Inc. (TRVI), a Delaware corporation and emerging growth company, on January 6, 2020. The report covers events occurring on December 31, 2019.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes rather than financial performance.
Material Changes
- Board Departure: On December 31, 2019, Eran Nadav, Ph.D., resigned from his position as a member of the Board of Directors.
- Reason for Departure: The resignation was not due to any disagreement with the Company regarding its operations, policies, or practices.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the standard disclosure regarding the director's resignation.
Investor Verification Checklist
- Confirm the effective date of Dr. Nadav's resignation (December 31, 2019).
- Verify if a replacement director has been appointed to fill the vacancy.
- Review the Company's most recent 10-K or 10-Q for financial metrics not included in this 8-K.